Business
Aeterna Zentaris Announces Poster Presentation of Phase 1/2 Results for AEZS-108 in Prostate Cancer at Upcoming European Society of Medical Oncology Congress
Jul. 7, 2011 (Canada NewsWire Group) -- QUÉBEC CITY, July 7, 2011 /CNW Telbec/ - Aeterna...
About this update from Cosciens Biopharma Inc.
[{"type":"text","content":"\n\n\n Jul. 7, 2011 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nQUÉBEC CITY, July 7, 2011 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the "Company")  today announced that an abstract on\n its anticancer compound, AEZS-108, has been accepted and will be\n presented during a poster session at the upcoming European Society of\n Medical Oncology Congress to be held September 23-27, 2011, at the\n Stockholm International Fairs in Stockholm, Sweden. AEZS-108, a\n targeted cytotoxic peptide conjugate, is currently in a Phase 1/2\n program in prostate and bladder cancer, and has successfully completed\n Phase 2 trials in endometrial and ovarian cancer.\n\n\n\n\n\n\n\nAbstract:  \n\n\n"A Phase I/II Trial of AEZS-108 (AN-152) in Castration-and\n Taxane-Resistant Prostate Cancer", S. V. Liu, A. V. Schally, T. Dorff, S. Groshen, D. Hawes, D. Quinn,\n Y.C. Tai, N. L. Block, J. Engel, and J. Pinski.\n\n\n\n\nPresenter: \n\n\nDr. Jacek Pinski, Associate Professor of Medicine at the Norris\n Comprehensive Cancer Center of the University of Southern California\n\n\n\n\nDate and time: \n\n\nSunday, September 24, 2011, 2:00 p.m. (local time)\n\n\n\n\nVenue: \n\n\nStockholm International Fairs, Stockholm, Sweden\n\n\n\n\nAbout AEZS-108\n\n\nAEZS-108 represents a new targeting concept in oncology using a hybrid\n molecule composed of a synthetic peptide carrier and a well-known\n chemotherapy agent, doxorubicin. Phase ...